ALLERGOLOGY INTERNATIONAL

TABLE OF CONTENTS

- Description ............................................. p.1
- Impact Factor .......................................... p.1
- Abstracting and Indexing ......................... p.1
- Editorial Board ........................................ p.2
- Guide for Authors .................................... p.3

DESCRIPTION

Allergology International is the official journal of the Japanese Society of Allergology and publishes original papers dealing with the etiology, diagnosis and treatment of allergic and related diseases. Papers may include the study of methods of controlling allergic reactions, human and animal models of hypersensitivity and other aspects of basic and applied clinical allergy in its broadest sense.

The Journal aims to encourage the international exchange of results and encourages authors from all countries to submit papers in the following three categories: Original Articles, Review Articles, and Letters to the Editor.

The acceptance criteria for all papers are the quality and originality of the research and its significance to our readership. Except where otherwise stated, manuscripts are peer reviewed by two anonymous reviewers and the Editor.

IMPACT FACTOR

2018: 3.965 © Clarivate Analytics Journal Citation Reports 2019

ABSTRACTING AND INDEXING

OCLC ArticleFirst
Science Citation Index Expanded
Web of Science
PubMed/Medline
Directory of Open Access Journals (DOAJ)
EBSCOhost
Embase
Scopus
Current Contents - Clinical Medicine
BIOSIS Previews
EDITORIAL BOARD

Editor-in-Chief
Hiroshi Nakajima, Chiba University, Chiba, Japan

Editorial Board
Cezmi A. Akdis, Davos, Switzerland
Koichiro Asano, Kanagawa, Japan
Thomas Bieber, Bonn, Germany
Jean Bousquet, Montpellier, France
Stephen J. Galli, Stanford, USA
Stephen T. Holgate, Southampton, UK
Chein-Soo Hong, Seoul, Korea
Kenji Izuhara, Saga, Japan
Naotomo Kambe, Osaka, Japan
Tak H. Lee, London, UK
Akira Matsuda, Tokyo, Japan
Hisako Matsumoto, Kyoto, Japan
Kenji Matsumoto, Tokyo, Japan
Hideaki Morita, Tokyo, Japan
Hiroyuki Murota, Nagasaki, Japan
Hiroyuki Nagase, Tokyo, Japan
Atsuhito Nakao, Yamanashi, Japan
Jae Won Oh, Seoul, Korea
Yusei Ohshima, Fukui, Japan
Nobuo Ohta, Miyagi, Japan
Mitsuhiro Okano, International University of Health and Welfare - Fukuoka Campus, Fukuoka, Japan
Thomas A. E. Platts-Mills, Charlottesville, USA
Johannes Ring, Munich, Germany
Sergio Romagnani, Florence, Italy
Hirohisa Saito, Tokyo, Japan
Robert Schleimer, Chicago, USA
Toshiro Takai, Tokyo, Japan
Takumi Takizawa, Gunma, Japan
Shigeharu Ueki, Akita, Japan
Gary Wong, Hong Kong, China
Masao Yamaguchi, Tokyo, Japan
Yukie Yamaguchi, Yokohama, Japan

Advisory Committee
K. F. Austen, Boston, USA
J. Bienenstock, Hamilton, Canada
L. M. Fabbri, Modena, Italy
S. Johansson, Karolinska Institute, Stockholm, Sweden
A. B. Kay, London, UK
T. Kishimoto, Osaka, Japan
F. B. M. Michel, Montpellier, France
A. L. Sheffer, Boston, USA
R. Siraganian, Bethesda, USA
R. F. Townley, Omaha, USA
GUIDE FOR AUTHORS

Submission of Manuscripts
All articles submitted to the journal must comply with these instructions. Failure to do so will result in return of the manuscript and possible delay in publication. Manuscripts should be written so that they are intelligible to the professional reader who is not a specialist in the particular field.

Peer review
This journal operates a single blind review process. All contributions are sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. For more information on the types of peer review, please visit: https://www.elsevier.com/reviewers/peer-review.

Online Submission
All manuscripts should be submitted and revised electronically using the ScholarOne Manuscript system at http://mc.manuscriptcentral.com/ai-jsa

Use of inclusive language
Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Articles should make no assumptions about the beliefs or commitments of any reader, should contain nothing which might imply that one individual is superior to another on the grounds of race, sex, culture or any other characteristic, and should use inclusive language throughout. Authors should ensure that writing is free from bias, for instance by using 'he or she', 'his/her' instead of 'he' or 'his', and by making use of job titles that are free of stereotyping (e.g. 'chairperson' instead of 'chairman' and 'flight attendant' instead of 'stewardess').

Prohibition of Double Publication
Papers are accepted for publication in the journal on the understanding that the content has not been published or submitted for publication elsewhere. This must be stated in the covering letter. The authors must be cautious even for review articles. Related works should be cross-referenced and any republished or translated material should indicate the appropriate permissions and acknowledgement. Submitted manuscripts will be checked by the CrossCheck (powered by iThenticate), the plagiarism checker software.

Ethical Review for Human Study
Authors must state that the protocol for the research project has been approved by a suitably constituted Ethics Committee (e.g. of the institution within which the work was undertaken). Experiments involving either human subjects or material of human origin should be carried out in accordance with the principles embodied in the Declaration of Helsinki of 1965 (as revised in Brazil 2013). All investigations on human subjects must include a statement that participants gave written informed consent and patient anonymity was preserved using methods approved by the Ethics Committee. This statement must be included in the text, in the Methods section. The approval number given by the Ethics Committee should be mentioned in the statement.

Preregistration for Clinical Trials
Clinical trials with interventional approach should be preregistered to a public registry approved by WHO, for example, http://www.clinicaltrials.gov, or http://www.umin.ac.jp/ctr/index-j.htm. The disclosed information should include primary outcomes in order to prohibit post hoc analysis based on researchers' prejudice. Information on registration must be given in the Abstract.

Guidelines for Animal Experiments
Authors should follow relevant guidelines for the care and use of laboratory animals. In the case of research involving recombinant DNA, experiments should be performed according to the guidelines issued by the authorized agency in the country in which the research was carried out. A note of the standards followed should be included in the Methods section.

Conflict of Interest (COI)
Each author who is listed on the title page should declare any financial support or relationships that may pose a conflict of interest. The corresponding author is required to confirm whether all authors have any conflicts of interest to declare, and to send the Conflict of Interest Disclosure Form (available
at [http://mc.manuscriptcentral.com/ai-jsa](http://mc.manuscriptcentral.com/ai-jsa) to the Editorial Office by fax at +81-(0)3-5807-1702, or the signed form can be uploaded on the online submission system. The COI statement should also be mentioned in the title page of the manuscript.

**Funding**

Articles should declare sources of support for the work, including sponsor names along with explanations of the role of those sources, if any, in study design; collection, analysis and interpretation of data; writing the report; or a statement declaring that the supporting source had no such involvement. All sources of funding of the study should be reported in the Acknowledgements.

**Authorship**

All people listed as authors of the manuscript should have contributed substantially to study planning, data collection or interpretation of results and have written or critically revised the manuscript and approved its final submitted version. Each individual's contribution to the work should be described in a short statement of Authors' Contributions on the title page.

*Statement example:* AB, CD, and EF designed the study and wrote the manuscript. GH and IJ contributed to data collection. KL performed the statistical analysis and interpretation of the results. All authors read and approved the final manuscript.

**Copyright**

Papers accepted for publication become the copyright of the Japanese Society of Allergology and all authors will be asked to sign a transfer of copyright form. In signing the transfer of copyright it is assumed that authors have obtained permission to use any copyrighted or previously published material. All authors must read, agree to the conditions outlined in the Copyright Transfer Form and must sign the Form. Articles cannot be published until a signed Copyright Transfer Form has been received.

**Author Rights**

As an author you (or your employer or institution) have certain rights to reuse your work. For more information on author rights, please see [https://www.elsevier.com/copyright](https://www.elsevier.com/copyright).

**Language**

Please write your text in good English. Non-native English authors are strongly recommended to have the English of the manuscript checked and improved by a language editing service before submission. Reviewers are not expected to correct grammatical errors and any deficiency in this area may detract from the scientific content and comprehensibility of the paper.

**Nomenclature**

Upon its first use in the title, abstract and text, the common name of a species should be followed by the scientific name (genus, species and authority) in parentheses. However, for well-known species, scientific names may be omitted from the article title. If no common name exists in English, the scientific name should be used. Generic, chemical, and/or proprietary names of drugs may be used. When a proprietary drug name is used, it should be followed parenthetically (at first mention only) by the full name of the manufacturer and the location. Authors should use the official allergen nomenclature approved by the World Health Organization (WHO) and the International Union of Immunological Societies (IUIS) Allergen Nomenclature Sub-Committee ([http://www.allergen.org](http://www.allergen.org)).

**Preparation of the Manuscript**

Submissions should be doubled-spaced with margins of 30 mm on all sides, and use a 12-point font, preferably Times New Roman. All pages should be numbered consecutively in the top right-hand corner, beginning with the title page. Add sequential line numbers throughout the manuscript. MS Word is the preferred format for an electronic file of the manuscript that can be submitted via the online submission system at [http://mc.manuscriptcentral.com/ai-jsa](http://mc.manuscriptcentral.com/ai-jsa). The journal will consider publication of the following article types: (1) ORIGINAL ARTICLE, (2) REVIEW ARTICLE and (3) LETTER TO THE EDITOR.

**Original Article**

The manuscript should be presented in the following order: title page; abstract and key words; list of abbreviations used; introduction; methods; results; discussion; acknowledgements; references; figure legends; tables (each table complete with title and footnotes) figures and supplementary materials. In general, an Original Article should not exceed 5000 words, not including the abstract, figure legends, and references. Each Original Article may have up to 8 figures and/or tables. For additional figures and tables, you may use Supplementary Materials described as below.
Title page: The title page should contain (i) the title of the paper, (ii) the full names of the authors and (iii) the addresses of the institutions at which the work was carried out together with (iv) the full postal and e-mail address, plus facsimile and telephone numbers, of the author to whom correspondence about the manuscript, proofs and requests for offprints should be sent. (v) Conflict of interest should be disclosed. Even if there is no conflict of interest, the statement should be included. Authors’ Contributions should also be included. The title should be short, informative and contain the major key words.

Abstract and key words: Articles must have a structured abstract that states in 250 words or less the purpose, basic procedures, main findings and principal conclusions of the study. Divide the abstract using the headings: Background, Methods, Results, and Conclusions. The abstract should not contain references. Five key words should be supplied in alphabetical order below the abstract and should be taken from those recommended by the Index Medicus Medical Subject Headings (MeSH) browser list (http://www.nlm.nih.gov/mesh/meshhome.html). Information on clinical trial registration should be included (if applicable) in the Abstract.

Abbreviations/acronyms: The abbreviations listed in the AI Abbreviations list may be used without definitions in the manuscript. If you use the abbreviations/acronyms not included in the List, provide their definitions in your list which should be included after the keywords.

Text: Authors should use subheadings to divide the sections of their manuscript: Introduction, Methods, Results, Discussion, Acknowledgements, and References.

Introduction: This section should include sufficient background information to set the work in context. The aims of the manuscript should be clearly stated. The introduction should not contain either findings or conclusions.

Methods: This should be concise but provide sufficient detail to allow the work to be repeated by others. The source of any materials should be given in detail, where possible. Ethical considerations should be detailed.

Results: Results should be presented in a logical sequence in the text, tables and figures; repetitive presentation of the same data in different forms should be avoided. The results should not contain material appropriate to the discussion.

Discussion: This should consider the results in relation to any hypotheses advanced in the introduction and place the study in the context of other work.

Acknowledgements: The source of financial grants and other funding should be acknowledged. All people who contributed considerably to the study reported in the manuscript or assisted in its writing but are not listed as authors should be mentioned in the Acknowledgements.

References: The Vancouver system of referencing should be used. In the text, references should be cited using superscript Arabic numerals in the order in which they appear. If cited only in tables or figure legends, number references according to the first identification of the table or figure in the text. In the reference list, the references should be numbered and listed in order of appearance in the text. Cite the names of all authors when there are six or fewer; when there are seven or more, list the first six authors followed by et al. Names of journals should be abbreviated in the style used in Index Medicus. Reference to unpublished data or personal communications should appear in the text only. For references to 'in press' articles, a final manuscript file of the accepted article should be included in the supplementary files when submitting. Authors must confirm in their covering letter that articles cited as "in press" have been accepted for publication. References should be listed in the following form.

Journal articles

Non-English journal articles

Books

Chapters in books

Figure legends: This should be self-explanatory and typed on a separate sheet. The legend should incorporate definitions of any symbols used, all abbreviations and units of measurement. Provide a text stating copyright authorization if figures have been reproduced from another source.

Tables: Tables should be self-contained and should complement, but not duplicate, information contained in the text. Tables should be numbered consecutively in Arabic numerals. Each table should be presented in a separate file with a comprehensive but concise legend above the table. Column headings should be brief, with units of measurement in parentheses; all abbreviations should be defined in footnotes. Footnote symbols: †, ‡, §, ¶ should be used (in that order) and *, **, *** should be reserved for P-values.

Figures: All illustrations (line drawings and photographs) are classified as figures.
- Each figure should be presented in a separate file.
- Figures should be cited in consecutive order in the text.
- Figure number should be indicated below or above the illustration.
- Figures should be submitted in their final sizes for print publication. The width should be 1-column (87.5 mm) or 2-column width (180 mm) for each figure.

Formats. If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as is' in the native document format. Regardless of the application used other than Microsoft Office, when your electronic artwork is finalized, please 'Save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):
- EPS (or PDF): Vector drawings, embed all used fonts.
- TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.
- TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.
- TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of 500 dpi.

More information can be found at https://www.elsevier.com/artworkinstructions.

Supplementary data may include additional figures, materials & methods, tables, or other items that can be published as online only as supplementary data, but cannot be included in the body of the paper. All supplementary data files will be reviewed along with the paper; these will not be published unless they significantly enhance the paper. Supplementary figures and tables should be named Supplementary Figure 1, Supplementary Table 1, etc.

Revisions: When submitting the revision, please upload both marked and un-marked version of the manuscript on the submission system. Also, please respond to all the queries raised by the reviewers and editors via "Author's response" in a point-by-point manner.

(2) Review Article

Review articles can be submitted either upon specific invitation or non-commissioned. The manuscript should be presented in the following order: title page; abstract of up to 250 words with 5 key words; abbreviations (if applicable); main text with several headings set by the author; acknowledgements; references; figure legends; tables and figures. In general, a Review Article should not exceed 5000 words, not including the abstract, figure legends and references. Each Review Article may have up to 10 figures and/or tables. Reviews should present an update of the most recent development in a particular field of allergy.
(3) Letter to the Editor
Letters to the Editor are brief reports of clinical or laboratory observations without sufficient depth of investigation to qualify as original articles, and begin with the salutation "Dear Editor". The average Letter to the Editor fills 2 pages in the printed journal, although manuscripts that exceed this may be occasionally accepted for publication at the Editors’ discretion. In general, a Letter to the Editor should not exceed 1000 words, not including the figure legends and references. Letters must have no more than ten references and a total of 2 figures and/or tables. There should be no headings. **Special note regarding case reports:** Case reports will only be considered for publication in the Letters to the Editor section of the Journal.

Open Access
Every peer-reviewed research article appearing in this journal will be published open access. This means that the article is universally and freely accessible via the internet in perpetuity, in an easily readable format immediately after publication. The author does not have any publication charges for open access. Japanese Society of Allergology will pay to make the article open access. A CC user license manages the reuse of the article (see [https://www.elsevier.com/openaccesslicenses](https://www.elsevier.com/openaccesslicenses)). All articles will be published under the following license:

**Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)**
For non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

Publication Fees
**Submission Fee:** A submission fee $30.00 is charged to the authors. If the Corresponding Author is a member of the Japanese Society of Allergology (JSA), the fee is waived. An author of a Letter to the Editor, who submits as a result of the Transfer to Letter, is not charged for the second submission.

**Page charges:** There are no page charges for articles.

**Offprints:** Both corresponding and co-authors may order offprints at any time via Elsevier’s WebShop at [http://webshop.elsevier.com/myarticleservices/offprints](http://webshop.elsevier.com/myarticleservices/offprints).

**Color figures:** If an accepted article includes color figures, these figures will appear in color online as well as in print at no additional charge.

General
Our requirements for submitted manuscripts that are not mentioned in the Instruction for Authors, are in accordance with the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals by International Committee of Medical Journal Editors (ICMJE) available online at [http://www.icmje.org](http://www.icmje.org).

© Copyright 2018 Elsevier | [https://www.elsevier.com](https://www.elsevier.com)